Study of ATTO 1091 for ulcerative colitis and healthy volunteers
Part of Digestive system clinical trials.
This study tests a new medicine called ATTO 1091 to see if it is safe and how the body handles it. It is for healthy adults and for people with moderate to severe ulcerative colitis, to help find new ways to treat this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old for the ulcerative colitis part, or 18 to 60 for the healthy volunteer part.
- Your weight must be between 45 and 125 kg, with a body mass index (BMI) in a specific range depending on the group.
- For ulcerative colitis: you must have a confirmed diagnosis for at least 3 months and have moderate to severe disease activity.
- For ulcerative colitis: you must not have tried more than 3 advanced therapies, or you have not responded to them.
- You must be generally healthy, with no serious infections, cancers, or other significant medical conditions.
- You must not be pregnant and must agree to use contraception if you can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational oral drug for ulcerative colitis. It is an early-stage trial to check safety and how the drug is processed by the body in both healthy volunteers and patients with active ulcerative colitis.
This study tests an investigational pill for people with moderate-to-severe ulcerative colitis that has not improved with standard treatments. The goal is to see if the pill can reduce symptoms like bloody stools and frequent bowel movements.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.